GSK (LSE/NYSE:GSK) has wrapped up its acquisition of the privately-held biopharma Affinivax. Cambridge, Massachusetts–based Affinivax has established a vaccine technology platform known as Multiple Antigen Presentation System (MAPS), designed to elicit a strong B-cell and T-cell immune response. GSK was attracted to Affinivax, given its aim to bolster its portfolio of specialty medicines and vaccines. …